James Khatcheressian, MD
Hematology & Oncology · Richmond, VANPI 1366536674
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,899 of the $22,961 with a category attached, or 78.0%. Daiichi Sankyo Inc. accounts for 80.2% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $10,052 and has fallen 63.5% since, to $3,672 in 2025. Among hematology & oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $276.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$18K
- Onmark, Inc.$3K
- Johnson & Johnson$209
- Novartis$139
- GSK$120
- Pfizer$98
- plus $663 from 20 others
Across 36 payments — averaging $20,838 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$676K
- Genentech, Inc.$63K
- Gilead$5K
- Portola Pharmaceuticals, LLC$4K
- AstraZeneca$2K
What the payments were for
- Consulting fees$17,89978%
- Travel & lodging$2,20310%
- Food & beverage$2,79912%
- Education$400%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 15 | $18,426 |
| Onmark, Inc. | 10 | $3,307 |
| Johnson & Johnson | 11 | $209 |
| Novartis | 5 | $139 |
| GSK | 5 | $120 |
| Pfizer | 5 | $98 |
| Merck | 4 | $76 |
| Gilead(2 entities) | 3 | $59 |
| Astellas Pharma US Inc | 3 | $53 |
| Eisai Inc. | 2 | $50 |
| Teva Pharmaceuticals USA, Inc. | 1 | $43 |
| Ipsen Biopharmaceuticals, Inc | 2 | $41 |
| AstraZeneca | 2 | $36 |
| AbbVie | 2 | $36 |
| CTI Biopharma Corp. | 1 | $33 |
| Boehringer Ingelheim | 1 | $31 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Seagen Inc. | 1 | $26 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $26 |
| Stemline Therapeutics Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| G1 Therapeutics, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $16 |
| Novocure Inc. | 1 | $16 |
| Taiho Oncology, Inc. | 1 | $16 |
| ADC Therapeutics America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$18,389
How this compares
$22,961 in reported general payments places this provider in the 90th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 52 | $813,391 |
| BrukinsaZanubrutinib | 53 | $740,318 |
| CalquenceAcalabrutinib Maleate | 22 | $329,243 |
| KisqaliRibociclib Succinate | 20 | $310,334 |
| RevlimidLenalidomide | 24 | $304,123 |
| InlytaAxitinib | 13 | $271,447 |
| PomalystPomalidomide | 11 | $247,280 |
| ImbruvicaIbrutinib | 17 | $242,070 |
| EliquisApixaban | 147 | $97,757 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $82,828 |
| XareltoRivaroxaban | 32 | $27,545 |
| Everolimus | 19 | $25,378 |
| Letrozole | 341 | $10,533 |
| Exemestane | 36 | $5,052 |
| Anastrozole | 259 | $4,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Inlyta, Eliquis, Octagam | $98 | $1,265,423225 claims |
| AstraZenecaCalquence | $36 | $329,24322 claims |
| NovartisKisqali | $139 | $310,33420 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $22 | $247,28011 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $26 | $242,07017 claims |
| Johnson & JohnsonXarelto | $209 | $27,54532 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $43 | $21034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Richmond
- Victor YazbeckRichmond$190K
- Attique SamdaniRichmond$104K
- Elke FriedmanRichmond$23K
- Rachit KumarRichmond$12K
- Gisa SchunnRichmond$8K
- Asit PaulRichmond$7K
- Pablo GonzalezRichmond$6K
- Hashim MannRichmond$6K
- Joshua McFarlaneRichmond$6K
- Ruby KochharHampton$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.